Funding for this research was provided by:
National Health and Medical Research Council (GNT1145997)
Received: 23 February 2022
Accepted: 9 June 2022
First Online: 30 June 2022
: All methods were carried out in accordance with relevant guidelines and regulations. Informed consent was obtained from all subjects and/or their legal guardian. This study was approved by the Australian National University Human Research Ethics Committee (Reference No. 2016/426), ACT Health Human Research Ethics Committee (Reference No. ETH.8.17.168), Qld Health Human Research Ethics Committee (Reference No. RD007108), HNE Human Research Ethics Committee (Reference No. 17/08/16/4.03), and the University of Melbourne Office of Research Ethics and Integrity (Reference No. 1750366.1). Human ethics approval was obtained for patients with campylobacteriosis in the ACT, NSW, and Qld as part of the CampySource case–control study. LV received ethics approval from the University of Queensland Human Research Ethics Committee during her candidature (ethics ID: 2017001121/HRE2016-0464).
: Not applicable.
: The authors declare that they have no competing interests.